GI CANCER TRANSLATIONAL
Research type
Research Study
Full title
Investigating molecular markers in samples collected from patients who took part in the QUASAR 2, VICTOR and SCOT trials
IRAS ID
173745
Contact name
David Church
Contact email
Sponsor organisation
University of Oxford
Duration of Study in the UK
10 years, 0 months, 1 days
Research summary
The QUASAR 2 trial looked at whether treating patients who had undergone surgery for bowel cancer, with a novel drug called bevacizumab, led to a decreased rate of recurrence of cancer and longer overall survival. All patients received standard drug capecitabine and half the patients received the new drug in addition to capecitabine.
The VICTOR trial looked at whether treating patients with rofecoxib (VIOXX)for either 2 or 5 years would improve relapse-free survivial after potentially curative surgery for colorectal cancer. Patients were randomised to either VIOXX or placebo for 2 or 5 years.
The SCOT trial looked at the assessment of the efficacy of 12 weeks versus 24 weeks of adjuvant chemotherapy with either oxaliplatin/5FU (OxMdG) or oxaliplatin/capecitabine(XELOX). There was also an economic analysis of the cost effectiveness of the 2 arms.
We collected blood samples and tumour samples from these patients. We have been studying in the laboratory whether these samples can identify 'markers' which relate to the risk of recurrence in the patients, or how well they will respond to the new drug. We also wish to perform basic science investigations that work out how these cancers grow. These are called prognostic and predictive markers. We have already found some interesting results, and have published some of these, but want to continue this critical work to improve outcomes for patients of the future.REC name
North West - Liverpool Central Research Ethics Committee
REC reference
17/NW/0252
Date of REC Opinion
11 Apr 2017
REC opinion
Favourable Opinion